Pathological truncations of human brain proteins represent the common feature of many neurodegenerative disorders including AD (Alzheimer's disease), Parkinson's disease and Huntington's disease. Protein truncations significantly change the structure and function of these proteins and thus can engender their pathological metamorphosis. We have shown previously that truncated forms of tau protein are contained in the core of the paired helical filaments that represent the main constituent of neurofibrillary pathology. Recently, we have identified truncated tau species of a different molecular signature. We have found that tau truncation is not produced by a random process, but rather by highly specific proteolytic cleavage and/or nonenzymatic fragmentation. In order to characterize the pathophysiology of AD-specific truncated tau species, we have used a transgenic rat model for AD expressing human truncated tau. Expression of the tau protein induces the formation of novel truncated tau species that originate from both transgenic human tau and endogenous rat tau proteins. Moreover, these truncated tau proteins are found exclusively in the misfolded fraction of tau, suggesting that they actively participate in the tau misfolding process. These findings corroborate further the idea that the appearance of truncated tau species starts a self-perpetuating cycle of further tau protein truncation leading to and accelerating tau misfolding and formation of neurofibrillary pathology.
AD (tau) [3] [4] [5] [6] [7] [8] [9] [10] [11] , Pick's disease (tau) [12, 13] , corticobasal degeneration (tau) and progressive supranuclear palsy (tau) [14] , FTLD {TDP-43 [TAR (transactivation response) DNA-binding protein of 43 kDa]} [15, 16] and PD (α-synuclein) [17] , as well as polyglutamine diseases such as HD (huntingtin) [18, 19] , spinocerebellar ataxia type 3 (ataxin-3) [20, 21] and spinocerebellar ataxia type 7 (ataxin-7) [22] , are proteolytically cleaved. Proteolysis can generate fragments with toxic gain-of-function that can be translocated into an inappropriate cell compartment. Pathological cleavage fragments can either switch on the cell death cascade or induce and drive protein aggregation. Mounting experimental evidence supports the idea that truncated protein fragments are upstream in the proteopathic cascade in these diseases and can form the initial seeds for the aggregation [16, [22] [23] [24] [25] [26] . We have shown that truncated tau protein induced and drove neurofibrillary degeneration in the transgenic rat brains [22, 23] . Moreover, truncated tau sequestered endogenous rat tau into the insoluble tau complexes [22, 23] . Similarly, TDP-43, which is a major component of the tau-negative and ubiquitin-positive inclusions in ALS (amyotrophic lateral sclerosis) and a subtype of FTLD (FTLD-TDP) [27] is proteolytically cleaved. Cleavage of TDP-43 leads to generation of the C-terminal fragments that are sufficient to initiate cytoplasmic mislocalization, ubiquitination, phosphorylation and aggregation [16] . It has been also shown that C-terminally truncated α-synuclein can seed the aggregation of wild-type α-synuclein [26] . Finally, an N-terminal fragment of huntingtin containing the polyglutamine expansion initiates a toxic cycle that leads to neuronal dysfunction and the neuropathological abnormalities in HD [24] .
Neurodegeneration-inducing proteins are substrates for many proteases including caspases, calpains, cathepsins and metalloproteinases. It has been shown that caspase-3-cleaved huntingtin fragments are detectable in HD brain before clinical onset [28, 29] . In AD brain, caspase-3-or -6-cleaved tau fragments are associated with both early and late NFTs (neurofibrillary tangles) and well correlate with cognitive decline [8, 9, 11] . Similarly, caspase-cleavage fragments of α-synuclein [17] , ataxin 3 [20, 21] and ataxin 7 [30] have been identified in other NDDs. These findings substantiate further the idea that protein truncation represents the most productive post-translational modification and plays the central role in the pathogenesis of human NDDs.
Tau truncation in AD: from discovery to therapy
In AD and other tauopathies, microtubule-associated protein tau undergoes a number of post-translational modifications resulting in the formation of misfolded protein forms that accumulate in the body (NFTs) and processes (e.g. dystrophic neurites or neuropil threads) of selectively vulnerable neurons.
The fine structure of the NFTs in AD was investigated in the 1960s using electron microscopy of tissue sections. Michael Kidd had published electron microscopic images of the structural subunits of the NFTs and called them PHFs (paired helical filaments) because of their appearance as two filaments helically wound around each other [31] . The molecular nature of PHFs was uncovered only about 20 years after the discovery of PHFs. Early immunological studies showed that tau protein was associated with PHFs [32] [33] [34] [35] [36] . However, other proteins were also linked with PHFs, including amyloid β-peptide, ubiquitin, MAP2 (microtubule-associated protein 2) and vimentin [37] [38] [39] [40] [41] [42] . All of these works suffered from the inherent inability to distinguish between molecules merely associated with PHFs and those that form a structural part of it. Klug and coworkers tackled the problem by stripping the PHFs isolated from the human AD brain from the associated proteins by treatment with pronase [3, 4, 43] . This approach permitted them to distinguish between the protease-sensitive PHF 'fuzzy coat', which includes the PHF-associated proteins, and the protease-resistant PHF core, the structural unit of PHF. mAb (monoclonal antibody) 423, raised against the highly purified protease-resistant PHF core [43] , was used to identify the PHF core-derived protein fragments of 12 and 9.5 kDa. Their N-terminal amino acid analysis showed that they are part of microtubule-associated protein tau. These experiments unequivocally established that tau is the structural constituent of the PHF core [3, 4, [44] [45] [46] . Furthermore, the experiments suggested that tau in PHFs is truncated. This suggestion was supported by the findings of Nieto et al. [5] who isolated a 33 kDa N-terminally truncated tau from PHFs purified from human AD brains.
The first in situ evidence of tau truncation in human AD brains was, however, provided by mAb 423. Epitope mapping revealed that the antibody recognized only tau proteins Cterminally truncated at Glu 391 [6] . Immunohistochemical analysis showed that mAb 423 decorates numerous NFTs in the brains of AD patients, whereas no tau proteins are recognized in normal healthy human brains [47] . These experiments showed that tau truncation is a part of the pathological process of tau protein misfolding in AD.
The protease resistance of the 12 kDa tau fragments identified in core PHFs led to the suggestion that they might have properties similar to those of prions [7] . These truncated tau proteins were termed 'tauons' and they were expected to undergo self-assembly into PHF in selected neuronal cells in AD brains. Novák [7] also suggested that truncation and phosphorylation are the possible mechanisms that transform normal tau into tauons.
Experiments on apoptosis in cerebellar granule neurons revealed that tau is cleaved by caspase 3 and calpain in cells undergoing apoptosis, resulting in a 17 kDa tau fragment [48] . Subsequently, the precise site in tau polypeptide cleaved by activated caspase 3 was identified as Asp 421 [49] . Finally, the presence of this caspase-cleavage product of tau in AD brains was also confirmed by TauC3 and α-Tau antibodies [8, 11] .
In vitro studies of tau aggregation indicated that the Cterminal part of tau had a rather inhibitory effect on the process and both naturally occurring truncations, at Glu 391 and Asp 421 , led to tau proteins more prone to aggregation than full-length tau [50, 51] . Expression of a truncated tau molecule tau-(151-421) in hippocampal neurons led to the induction of apoptosis, suggesting that caspase cleavage of tau at Asp 421 turns it into an apoptosis effector molecule [49] . It has been shown that the truncated tau proteins induced mitochondrial fragmentation and elevated oxidative stress in comparison with cells expressing full-length tau [52, 53] . In summary, these data supported the notion that truncation of tau could generate tauon-like elements with toxic gain-offunction.
The presumed properties of tauons [7] suggest that these truncated tau species have a conformation different from that of normal tau proteins. This view was supported by mAb DC11, a novel type of truncation-dependent conformational antibody, which recognizes abnormal tau proteins in the AD brains [54] . This antibody does not recognize normal tau proteins present in the non-demented control brain. The AD-specific conformation of tau recognized by DC11 can be reconstituted in recombinant tau proteins through their truncation either at the N-terminus or at both the N-and C-termini, without the necessity of a site-specific cleavage point. Therefore the conformational antibody DC11 revealed that a plethora of N-and C-terminally truncated tau species possess pathological conformations proposed for tauons. We have found that tauons exhibited loss of normal function by inducing abnormal microtubule assembly. In order to validate pathological activity in vivo, we have expressed the most pathogenic form of human truncated tau protein (amino acids 151-391, 4R, and amino acids 151-391, 3R) as a transgene, in the rat brain [23, 24] . The expression of the truncated tau proteins in the brain of transgenic animals induced the complete tau cascade of neurofibrillary degeneration as found in humans. Truncated tau induced tau hyperphosphorylation, formation of Gallyas-positive intracellular and extracellular tangles also exhibiting Congo Red birefringence and thioflavin S reactivity, formation of sarkosyl-insoluble misfolded tau complexes containing both truncated and endogenous rat tau. Moreover, the misfolded endogenous rat tau formed the A68 triplet characteristic of AD [23, 24] . At the systemic level, expression of the truncated tau protein induced oxidative stress [52] and neuroinflammation [55] . Thus, in contrast with full-length tau, truncated tau induced the complete tau neurofibrillary cascade accompanied by neurobehavioural impairment and oxidative stress, generating one of the most comprehensive models of tau neurodegeneration.
Recently, de Calignon et al. [25] have shown that transient activation of executioner caspases in neurons of Tg4510 transgenic mice expressing mutant tau P301L, or mice expressing 4R wild-type human tau, led to tau cleavage at Asp 421 and formation of thioflavin S-positive intraneuronal tau NFTs and the appearance of tangle-related conformational epitopes. These in vivo data confirmed that truncation causes conformational changes of tau that induce the misfolding cascade in AD. Tau truncation is therefore a valid target for disease-modifying therapy aimed at halting the progression of AD.
Tau truncation in AD is not a random process
We have shown previously that truncated tau species are the most prevalent in sarkosyl-insoluble brain tissue fractions [23, 54] . To decrease the level of complexity of this insoluble tau proteome, we have performed tandem-affinity purification using specific mAbs. This allowed us to separate tau species with an intact N-terminus, intact C-terminus and various double-truncated tau proteins (Figure 1 ). Monoclonal antibody DC31N that recognizes the very N-terminal part of human tau protein was able to pull-down predominantly tau molecules comprising the AD-specific A68 signature [56] . This shows that truncation of aggregated tau protein occurs almost exclusively from the N-terminus (DC31N) which is in agreement with discovery of the C-terminal microtubulebinding repeat regions being the aggregation-prone domains [45] . Tau proteins that passed through the DC31N column were fractionated further on a DC39C column to immunopurify tau proteins with intact C-termini. Tau proteins captured by DC39C represent a family of N-terminally truncated tau proteins that appear to group into distinct protein bands ( Figure 1B , brackets in DC39C lane). This suggests that N-terminal tau protein truncation is a regulated process with several preferential cleavage sites within the tau molecule. In addition, truncated tau proteins are subjected to post-translational modifications that cause a significant and systematic shift in their electrophoretic mobility (e.g. ubiquitination), resulting in groups of protein bands on SDS gels. These data imply that N-terminal truncation of tau protein in human AD brain is not a random process.
In the last purification step, tau proteins lacking both intact termini were concentrated using a DC190 column.
They represent a tau protein family with a wide spectrum of molecular sizes ranging from 10 kDa to high-molecular-mass aggregates with several distinct bands. MS analysis of lowmolecular-mass proteins ( Figure 1B , the bracket in DC190 lane) has identified the core PHF polypeptides that were described by Jakes et al. [45] (results not shown). This proves the existence of truncated PHF core tau fragments in the core of PHF not dependent on the pre-treatment with pronase or other proteolytic agents [3, 4] .
Truncated tau induces further fragmentation of tau proteins
The main problem in identification of AD-relevant tau truncations is the fact that human brain tissue samples are only available after a certain post-mortem delay that might have caused a general non-specific degradation of cellular and other proteins. In order to distinguish between this nonspecific degradation and disease-specific truncation, we have taken advantage of the AD transgenic rat model expressing truncated 3R tau protein [24] . We have shown previously that SHR24 transgenic rats developed progressive age-dependent neurofibrillary pathology in the cortex. NFTs were detected by several antibodies recognizing pathologically modified tau in the human brain including DC11. Moreover, neurofibrillary degeneration was characterized by extensive formation of sarkosyl-insoluble tau protein complexes consisting of both rat endogenous and human transgenic truncated tau [24] .
In our study, sarkosyl-insoluble tau proteins were prepared from the brain cortex of the animals with advanced tau pathology with post-mortem delay of less that 1 min. Intact human transgenic tau product has been removed using a DC18 column (mAb recognizing human tau sequence 168-181) and N-terminally truncated transgenic and other tau species were concentrated on a DC190 column ( Figure 2B ). Transgenic tau protein migrates as a broad band consisting of multiple phosphorylated species ( Figure 2B , DC18 lane). In addition, its higher-molecular-mass complexes reaching 70 kDa are also detectable. Isolated truncated tau proteins by DC190 immuno-pull-down range from 10 to 30 kDa. Comparison of the protein pattern within this region between the original sample (P2) and DC190 eluate ( Figure 2B , both DC25 immunodetection and Coomassie Brilliant Blue staining) clearly shows that all truncated tau proteins identified are present in the starting material and were therefore not created during the purification procedure.
When immunofractionated tau proteins were probed for an intact C-terminus, endogenous rat tau proteins forming the AD-characteristic A68 signature were clearly identified ( Figure 2C ). In addition, truncated fragments originating from the rat tau proteins was detected with a molecular mass of approximately 35 kDa. Therefore expression of human truncated tau transgene not only has caused truncation and aggregation of its own, but also has been able to engage endogenous rat tau proteins in the fragmentation and aggregation processes. This means that the transgenic not the transgene, which lacks the C-terminus. (B) Sarkosyl-insoluble fraction (P2) from SHR24 rat cortex brain samples was prepared and treated as described in Figure 1 . The human transgene product was retained on the DC18 affinity column and truncated proteins together with rat tau species were captured using the DC190 column. Tau proteins were immunodetected by mAb DC25 (amino acids 347-353).
Purity of the final sample was assessed by Coomassie Brilliant Blue (CBB) staining (DC190/CBB). (C) Immunostaining of the fractionated P2 sample (as described above) with C-terminus-specific mAb DC39C. Six recombinant human tau isoforms together with recombinant transgene product (amino acids 151-391, 3R) served as molecular mass and antibody-specific references (6i + AT3R). Molecular masses (M) are indicated in kDa. HRP, horseradish peroxidase; WB, Western blot truncated tau is sufficient to initiate and drive the tau truncation cascade in the rat brain tissue.
Conclusion
Although NDDs differ in the cause, the onset, progression and clinical picture, they share the main common feature: formation of toxic protein fragments. It has been shown that protein truncations can significantly change the structure and function of the proteins that can finally lead to the loss of their normal function and the gain of toxic function. In AD, we have identified truncated tau species that are enriched in the core of the PHFs. The filaments represent the main constituent of AD neurofibrillary pathology. In the present paper, we describe evidence that AD brains contain various truncated tau species of different molecular signatures. Moreover, we have found that tau truncation is not produced by a random process, but rather by highly specific proteolytic cleavage and non-enzymatic fragmentation. In order to characterize the pathophysiology of AD-specific truncated tau species, we have used a transgenic rat model for AD-expressing human truncated tau. Its expression induces formation of novel truncated tau species that originate from both transgenic human tau and endogenous rat tau proteins. Moreover, these truncated tau proteins are found in the sarkosyl-insoluble fraction of tau, suggesting that they actively participate in the tau-driven neurodegenerative process. Current evidence shows that truncated tau species not only are the driving force behind the neurofibrillary degeneration, but also serve as a prototype for generation of novel truncated forms that finally speed up the tangle formation. 
